Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Rituximab 12acalabrutinib 9Cyclophosphamide 9zanubrutinib 7ibrutinib 7Magnetic Resonance Spectroscopy 5venetoclax 4fludarabine 4Lenalidomide 4Cytarabine 4Cyclosporine 4CT-P10 4obinutuzumab 3fludarabine phosphate 3Whole-Body Irradiation 3Vincristine 3Specimen Handling 3Mycophenolic Acid 3Methotrexate 3Doxorubicin 3Bendamustine Hydrochloride 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Immunotherapy, Adoptive 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × loncastuximab tesirine × 30 days × Clear all
NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡